Crystallographic and computational studies on 4-phenyl-N-(β-D- glucopyranosyl)-1H-1,2, 3-triazole-1-acetamide, an inhibitor of glycogen phosphorylase: Comparison with α-D-glucose, N-acetyl-β-D- glucopyranosylamine and N-benzoyl-N′-β-D-glucopyranosyl urea binding

Proteins: Structure, Function and Genetics

Volumn 71, Issue 3, 2008, Pages 1307-1323

  Alexacou, Kyra Melinda ^a   Hayes, Joseph M ^a   Tiraidis, Costas ^a   Zographos, Spyros E ^a   Leonidas, Demetres D ^a   Chrysina, Evangelia D ^a   Archontis, Georgios ^b   Oikonomakos, Nikos G ^a   Paul, Jashuva V ^c   Varghese, Babu ^c   Loganathan, Duraikkannu ^c  

^a INSTITUTE OF BIOLOGY   (Greece)

^b UNIVERSITY OF CYPRUS   (Cyprus)

^c INDIAN INSTITUTE OF TECHNOLOGY MADRAS   (India)

Author keywords

Docking; Glucose; Glucosyltriazolylacetamide; Glycogen phosphorylase; Inhibition; Molecular dynamics; Type 2 diabetes; X ray crystallography

Indexed keywords

4 PHENYL N BETA DEXTRO GLUCOPYANOSYL 1H 1,2,3 TRIAZOLE 1 ACETAMIDE; ALPHA GLUCOSE; ENZYME INHIBITOR; GLUCOSE DERIVATIVE; GLYCOGEN PHOSPHORYLASE; N ACETYL BETA DEXTRO GLUCOPYRANOSYLAMINE; N BENZOYL N BETA DEXTRO GLUCOPYRANOSYL UREA; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; CALCULATION; CHEMICAL BOND; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; ENZYME ACTIVE SITE; ENZYME BINDING; ENZYME KINETICS; GLYCOGEN SYNTHESIS; HYDROGEN BOND; LIGAND BINDING; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR MODEL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REPRODUCIBILITY; SIMULATION; STRUCTURE ANALYSIS; X RAY CRYSTALLOGRAPHY;

ANIMALS; AZIDES; BINDING SITES; COMPUTATIONAL BIOLOGY; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; GLUCOSAMINE; GLUCOSE; GLYCOGEN PHOSPHORYLASE; PROTEIN BINDING; RABBITS; UREA;

EID: 42449155497     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.21837     Document Type: Article

References (92)

1. Newgard CB, Hwang PK, Fletterick RJ. The family of glycogen phosphorylases: structure and function. Crit Rev Biochem Mol Biol 1989;24:69-99.
2. McCormack JG, Westergaard N, Kristiansen M, Brand CL, Lau J. Pharmacological approaches to inhibit endogenous glucose production as a means of anti-diabetic therapy. Curr Pharm Des 2001;7: 1451-1474.
3. Treadway JL, Mendys P, Hoover DJ. Glycogen phosphorylase inhibitors for treatment of type 2 diabetes mellitus. Expert Opin Invest Drugs 2001;10:439-454.
4. Oikonomakos NG. Glycogen phosphorylase as a molecular target for type 2 diabetes therapy. Curr Protein Pept Sci 2002;3:561-586.
5. Somsák L, Nagy V, Hadady Z, Docsa T, Gergely P. Glucose analog inhibitors of glycogen phosphorylases as potential antidiabetic agents: recents developments. Curr Pharm Des 2003;9:1177-1189.
6. Sarabu R, Tilley J. Recent advances in therapeutic approaches to type 2 diabetes. Annu Rep Med Chem 2005;40:167-181.
7. Somsák L, Nagy V, Hadady Z, Felföldi N, Docsa T, Gergely P. Recent developments in the synthesis and evaluation of glucose analog inhibitors of glycogen phosphorylases as potential antidiabetic agents. In: Reitz AB, Kordik CP, Choudhary MI, Atta ur R, editors. Frontiers in medicinal chemistry, Vol. 2. Bentham Science Publishers Ltd: Hilversum, The Netherlands, 2005. pp 253-272.
8. Oikonomakos NG, Tiraidis C, Leonidas DD, Zographos SE, Kristiansen M, Jessen CU, Nørskov-Lauritsen L, Agius L. Iminosugars as potential inhibitors of glycogenolysis: structural insights into the molecular basis of glycogen phosphorylase inhibition. J Med Chem 2006;49:5687-5701.
9. Anagnostou E, Kosmopoulou MN, Chrysina ED, Leonidas DD, Hadjiloi T, Tiraidis C, Györgydeák Z, Somsák L, Docsa T, Gergely P, Oikonomakos NG. Crystallographic studies on two bioisosteric analogues. N-acetyl-β-D-glucopyranosylamine and N- trifluoracetyl-β-D-glucopyranosylamine, potent inhibitors of muscle glycogen phosphorylase. Bioorg Med Chem 2006;14:181-189.
10. Watson KA, Mitchell EP, Johnson LN, Cruciani G, Son JC, Bichard CJF, Fleet GWJ, Oikonomakos NG, Kontou M, Zographos SE. Glucose analogue inhibitors of glycogen phosphorylase: from crystallographic analysis to drug prediction using GRID force-field and GOLPE variable selection. Acta Crystallogr 1995;D51:458-472.
11. Aich U, Lakshmanan T, Varghese B, Loganathan D. Crystal structures of beta-1-N-chloroacetamido derivatives of D-glucose and D-galactose. J Carb Chem 2003;22:891-901.
12. Oikonomakos NG, Kosmopoulou M, Zographos SE, Leonidas DD, Chrysina ED, Somsák L, Nagy V, Praly J-P, Docsa T, Tóth B, Gergely P. The binding of N′-acetyl- and Benzoyl-N′-β-D- glucopyranosyl ureas to glycogen phosphorylase b: kinetic and crystallographic studies. Eur J Biochem 2002;269:1-13.
13. Aich U, Loganathan D. Synthesis of N-(beta-glycopyranosyl) azidoacetamides. J Carbohydr Chem 2005;24:1-4.
14. Sheldrick GM. SHELX97: program for the refinement of crystal structures. Gottingen, Germany: University of Gottingen; 1997.
15. Farrugia LJ. WinGX suite for small-molecule single-crystal crystallography. J Appl Crystalogr 1999;32:837-838.
16. Oikonomakos NG, Kontou M, Zographos SE, Watson KA, Johnson LN, Bichard CJF, Fleet GWJ, Acharya KR. N-acetyl-β-D- glucopyranosylamine: a potent T state inhibitor of glycogen phosphorylase. A comparison with α-D-glucose. Protein Sci 1995;4:2469-2477.
17. Oikonomakos NG, Melpidou AE, Johnson LN. Crystallisation of pig skeletal phosphorylase b. Purification, physical and catalytic characterization. Biochim Biophys Acta 1985;832:248-256.
18. Otwinowski Z, Minor W. Processing of x-ray diffraction data collected in oscillation mode. Methods Enzymol 1997;276:307-326.
19. Murshudov GN, Vagin AA, Dodson EJ. Refinement of macromolecular structures by the Maximum-Likelihood Method. Acta Crystallogr D 1997;53:240-255.
20. Gregoriou M, Noble MEM, Watson KA, Garman EF, Krulle TM, Fuente C, Fleet GWJ, Oikonomakos NG, Johnson LN. The structure of a glycogen phosphorylase glucopyranose spirohydantoin complex at 1.8 Å resolution and 100 K: the role of water structure and its contribution to binding. Protein Sci 1998;7:915-927.
21. Jones TA, Zou JY, Cowan SW, Kjeldgaard M. Improved methods for the building of protein models in electron density maps and the location of errors in these models. Acta Crystallogr A 1991;47:110-119.
22. Laskowski RA, MacArthur MW, Moss DS, Thornton JM. PROCHECK - a program to check the stereochemical quality of protein structures. J Appl Crystallogr 1993;26:283-291.
23. CCP4. The CCP4 (Collaborative Computational project Number 4) suite: programmes for protein crystallography. Acta Crystallogr D 1994;50:760-763.
24. Potterton E, McNicholas S, Krissinel E, Cowtan K, Noble M. The CCP4 molecular-graphics project. Acta Crystallogr 2002;D58:1955-1957.
25. Potterton L, McNicholas S, Krissinel E, Gruber J, Cowtan K, Emsley P, Murshudov GN, Cohen S, Perrakis A, Noble M. Development in the CCP4 molecular-graphics project. Acta Crystallogr D 2004;60: 2288-2294.
26. Glide, version 4.0. New York, NY: Schrodinger, LLC; 2005.
27. Gold, version 3.1.1. Cambridge Crystallographic Data Centre: Cambridge, UK, 2007.
28. Jorgensen WL, Maxwell DS, Tirado-Rives J. Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J Am Chem Soc 1996;118:11225-11236.
29. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shelley M, Perry JK, Shaw DE, Francis P, Shenkin PS. Glide: a new approach for rapid, accurate docking and scoring. I. Method and assessment of docking accuracy. J Med Chem 2004;47:1739-1749.
30. Jones G, Willett P, Glen RC. Molecular recognition of receptor-sites using a genetic algorithm with a description of desolvation. J Mol Biol 1995;245:43-53.
31. Jones G, Willett P, Glen RC, Leach AR, Taylor R. Development and validation of a genetic algorithm for flexible docking. J Mol Biol 1997;267:727-748.
32. Eldridge MD, Murray CW, Auton TR, Paolini GV, Mee RP. Empirical scoring functions. I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J Comput-Aided Mol Des 1997;11:425-445.
33. Baxter CA, Murray CW, Clark DE, Westhead DR, Eldridge MD. Flexible docking using Tabu search and an empirical estimate of binding affinity. Proteins 1998;33:367-382.
34. Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, Taylor RD. Improved protein-ligand docking using GOLD. Proteins 2003; 52:609-623.
35. MacroModel, version 9.1. New York, NY: Schrodinger, LLC; 2005.
36. Kaminski GA, Friesner RA, Tirado-Rives J, Jorgensen WJ. Evaluation and reparametrization of the OPLS-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides. J Phys Chem B 2001;105:6474-6487.
37. Still WC, Tempzyk A, Hawley R, Hendrickson T. Semianalytical treatment of solvation for molecular mechanics and dynamics. J Am Chem Soc 1990;112:6127-6129.
38. Gallicchio E, Zhang LY, Levy RM. The SGB/NP hydration free energy model based on the surface generalized born solvent reaction field and novel nonpolar hydration free energy estimators. J Comput Chem 2002;3:517-529.
39. Guvench O, Shenkin P, Kolossvary I, Still WC. Application of the frozen atom approximation to the GB/SA continuum model for solvation free energy. J Comput Chem 2002;23:1-8.
40. Archontis G, Watson KA, Xie Q, Andreou G, Chrysina ED, Zographos SE, Oikonomakos NG, Karplus M. Molecular recognition and relative binding of glucopyranose spirohydantoin analogues to glycogen phosphorylase: a free energy perturbation study. Proteins 2005;61:984-998.
41. van Gunsteren WF, Mark AE. Validation of molecular dynamics simulation. J Chem Phys 1998;108:6109-6116.
42. Schreiber H, Steinhauser O. Taming cutoff induced artifacts in molecular-dynamics studies of solvated polypeptides-The reaction field method. J Mol Biol 1992;228:909-923.
43. Allen MP, Tildesley DJ. Computer simulation of liquids. Oxford: Clarendon Press; 1987.
44. Ryckaert JP, Ciccotti G, Berendsen HJC. Numerical-integration of cartesian equations of motion of a system with constraints-molecular-dynamics of N-alkanes. J Comput Phys 1977;23:327-341.
45. Martin JL, Veluraja K, Ross K, Johnson LN, Fleet GWJ, Ramsden NG, Bruce I, Orchard M, Oikonomakos NG, Papageorgiou AC, Leonidas DD, Tsitura HS. Glucose analogue inhibitors of glycogen phosphorylase: the design of potential drugs for diabetes. Biochemistry 1991;30:10101-10116.
46. Sriram D, Sreenivasan H, Srinivasan S, Priya K, Vishnu Thirtha M, Loganathan D. beta-1-N-acetamido-D-glucopyranose. Acta Crystallogr C 1997;53:1075-1077.
47. Hager C, Miethchen R, Reinke H. Organofluorine compounds and fluorinating agents. 27-New trifluoromethyl substituted 1,2,3-triazoles linked to D-galactose and D-gulose. J Prakt Chem-Chem-Zeitung 2000;342:414-420.
48. Eaton VJ, Steele D. Dihedral angle of biphenyl in solution and the molecular force field. J Chem Soc Faraday Trans 1973:2, 69, 1601-1608.
49. Loganathan D, Aich U, Lakshmanan T. Chemoenzymatic synthesis and X-ray crystallographic investigation of N-glycoprotein linkage region models and analogs. Proc Indian Natl Sci Acad71A:213-236, 2005.
50. Loganathan D, Aich U. Observation of a unique pattern of bifurcated hydrogen bonds in the crystal structures of the N-glycoprotein linkage region models. Glycobiology 2006;16:343-348.
51. Watson KA, Chrysina ED, Tsitsanou KE, Zographos SE, Archontis G, Fleet GWJ, Oikonomakos NG. Kinetic and crystallographic studies of glucopyranose spirohydantoin and glucopyranosylamine analogues inhibitors of glycogen phosphorylase. Proteins 2005;61:966-983.
52. Chrysina ED, Oikonomakos NG, Zographos SE, Kosmopoulou MN, Bischler N, Leonidas DD, Kovács L, Docsa T, Gergely P, Somsák L. Crystallographic studies on α- and β-D-glucopyranosyl formamide analogues, inhibitors of glycogen phosphorylase. Biocatal Biotransfor 2003;21:233-242.
53. Chrysina ED, Kosmopoulou MN, Kardakaris R, Bischler N, Leonidas DD, Kannan T, Loganathan D, Oikonomakos NG. Binding of β-D- glucopyranosyl bismethoxyphosphoramidate to glycogen phosphorylase b: kinetic and crystallographic studies. Bioorg Med Chem 2005;13:765-772.
54. Petsalakis EI, Chrysina ED, Tiraidis C, Hadjiloi T, Leonidas DD, Oikonomakos NG, Aich U, Varghese B, Loganathan D. Crystallographic studies on N-azidoacetyl-β-D-glucopyranosylamine, an inhibitor of glycogen phosphorylase: comparison with N-acetyl-β-D- glucopyranosylamine. Bioorg Med Chem 2006;14:5316-5324.
55. Bichard CJF, Mitchell EP, Wormald MR, Watson KA, Johnson LN, Zographos SE, Koutra DD, Oikonomakos NG, Fleet GWJ. Potent inhibition of glycogen phosphorylase by a spirohydantoin of glucopyranose: first pyranose analogues of hydantocidin. Tetrahedron Lett 1995;36:2145-2148.
56. Krülle TM, Watson KA, Gregoriou M, Johnson LN, Crook S, Watkin DJ, Griffiths RC, Nasj RJ, Tsitsanou AE, Zographos SE, Oikonomakos NG, Fleet GWJ. Specific inhibition of glycogen phosphorylase by a spirodiketopiperazine at the anomeric position of glucopyranose. Tetrahedron Lett 1995;36:8291-8294.
57. Brandstetter TW, Fuente C, Kim Y-h, Johnson LN, Crook S, Q. Lilley PM, Watkin DJ, Tsitsanou KE, Zographos SE, Chrysina ED, Oikonomakos NG, Fleet GWJ. Glucofuranose analogues of hydantocidin. Tetrahedron 1996;52:10721-10736.
58. Krülle TM, delaFuente C, Watson KA, Gregoriou M, Johnson LN, Tsitsanou KE, Zographos SE, Oikonomakos NG, Fleet GWJ. Stereospecific synthesis of spirohydantoins of beta-glucopyranose: inhibitors of glycogen phosphorylase. Synlett 1997;211-213.
59. Oikonomakos NG, Skamnaki VT, Ösz E, Szilágyi L, Somsák L, Docsa T, Tóth B, Gergely P. Kinetic and crystallographic studies of glucopyranosylidene spirothiohydantoin binding to glycogen phosphorylase b. Bioorg Med Chem 2002;10:261-268.
60. Chrysina ED, Kosmopoulou MN, Tiraidis C, Kardakaris R, Bischler N, Leonidas DD, Hadady Z, Somsák L, Docsa T, Gergely P, Oikonomakos NG. Kinetic and crystallographic studies on 2-(β-D-glucopyranosyl)-5- methyl-1,3,4-oxadiazole, -benzothiazole, and -benzimidazole, inhibitors of muscle glycogen phosphorylase b. Evidence for a new binding site. Protein Sci 2005;14:873-888.
61. Oikonomakos NG, Schnier JB, Zographos SE, Skamnaki VT, Tsitsanou KE, Johnson LN. Flavopiridol inhibits glycogen phosphorylase by binding at the inhibitor site. J Biol Chem 2000;275:34566-34573.
62. Tsitsanou KE, Skamnaki VT, Oikonomakos NG. Structural basis of the synergistic inhibition of glycogen phosphorylase a by caffeine and a potential antidiabetic drug. Arch Biochem Biophys 2000;384:245-254.
63. Chebotareva N, Klinov SV, Kurganov BI. Regulation of muscle glycogen phosphorylase by physiological effectors. Biotechnol Genet Eng Rev 2001;18:265-297.
64. Ekstrom JL, Pauly TA, Carry MD, Soeller WC, Culp J, Danley DE, Hoover DJ, Treadway JL, Gibbs EM, Fletterick RJ, Day YS, Myszka DG, Rath VL. Structure-activity analysis of the purine binding site of human liver glycogen phosphorylase. Chem Biol 2002;9:915-924.
65. Kaiser A, Nishi K, Gorin FA, Walsh DA, Bradbury EM, Schnier JB. The cyclin-dependent kinase (CDK) inhibitor flavopiridol inhibits glycogen phosphorylase. Arch Biochem Biophys 2001;386:179-187.
66. Hampson LJ, Arden C, Agius L, Ganotidis M, Kosmopoulou MN, Tiraidis C, Elemes Y, Sakarellos C, Leonidas DD, Oikonomakos NG. Regulation of hepatic glycogen metabolism by purine nucleoside site inhibitors of glycogen phosphorylase. Bioorg Med Chem 2006;14:7835-7845.
67. So S, Karplus M. A comparative study of ligand-receptor complex binding affinity prediction methods based on glycogen phosphorylase inhibitors. J Computer-Aided Mol Des 1999;13:243-258.
68. Marchand-Geneste N, Watson KA, Alsberg BK, King RD. New Approach to pharmacophore mapping and QSAR analysis using inductive logic programming. Application to thermolysin inhibitors and glycogen phosphorylase b inhibitors. J Med Chem 2002; 45:399-409.
69. Liu G, Zhang Z, Luo X, Shen J, Liu H, Shen X, Chen K, Jiang H. Inhibitory mode of indole-2-carboxamide derivatives against HLGPa: molecular docking and 3D-QSAR analyses. Biorg Med Chem 2004;12:4147-4157.
70. Pan D, Tseng Y, Hopfinger AJ, Quantitative Structure-Based Design: formalism and application of receptor-dependent (RD) 4D-QSAR analysis to a set of glucose analogue inhibitors of glycogen phosphorylase. J Chem Inf Comput Sci 2003;43:1591-1607.
71. Pan D, Liu J, Senese C, Hopfinger AJ, Tseng Y. Characterization of a ligand-receptor binding event using receptor-dependent four-dimensional quantitative structure-activity relationship analysis. J Med Chem 2004;47:3075-3088.
72. Deng Q, Lu Z, Bohn J, Ellsworth KP, Myers RW, Geissler WM, Harris G, Willoughby CA, Chapman K, McKeever B, Mosley R. Modeling aided design of potent glycogen phosphorylase inhibitors. J Mol Graph Model 2005;23:457-464.
73. de Graaf C, Oostenbrink C, Keizers PHJ, van der Wijst T, Jongejan A, Vermeiden NPE. Catalytic site prediction and virtual screening of cytochrome P450 2D6 substrates by consideration of water and rescoring in automated docking. J Med Chem 2006;49:2417-2430.
74. Bissantz C, Folkers G, Rognan D. Protein-based virtual screening of chemical databases. I. Evaluation of different docking/scoring combinations. J Med Chem 2000;43:4759-4767.
75. Kellenberger E, Rodrigo J, Muller P, Rognan D. Comparative evaluation of eight docking tools for docking and virtual screening accuracy. Proteins 2004;57:225-242.
76. Graves AP, Brenk R, Shoichet BK. Decoys for docking. J Med Chem 2005;48:3714-3728.
77. Cummings MD, DesJarlais RL, Gibbs AC, Mohan V, Jaeger EP. Comparison of automated docking programs as virtual screening tools. J Med Chem 2005;48:962-976.
78. Calimet N, Schaefer M; Simonson T. Protein molecular dynamics with the generalized Born/ACE solvent model. Proteins 2001;45: 144-158.
79. Cornell W, Abseher R, Nilges M, Case D. Continuum solvent molecular dynamics study of flexibility in interleukin-8. J Mol Graph Model 2001;19:136-145.
80. Majeux N, Scarsi M, Apostolakis J, Ehrhardt C, Caflisch A. Exhaustive docking of molecular fragments with electrostatic solvation. Proteins 1999;37:88-105.
81. Lee MS, Salsbury FR, Brooks CL. Constant-pH molecular dynamics using continuous titration coordinates. Proteins 2004;56: 738-752.
82. Simonson T, Carlsson J, Case D. Proton binding to proteins: pK(a) calculations with explicit and implicit solvent methods. J Am Chem Soc 2004;126:4167-4180.
83. Felts AK, Gallichio E, Wallqvist A, Levy R. Distinguishing native conformations of proteins from decoys with an effective free energy estimator based on the OPLS all-atom force field and the surface generalized Born solvent model. Proteins 2002;48:404-422.
84. Pokala N, Handel T. Energy functions for protein design. I. Efficient and accurate continuum electrostatics and solvation. Protein Sci 2004;13:925-935.
85. Archontis G, Simonson T. A residue-pairwise generalized Born scheme suitable for protein design calculations. J Phys Chem B 2005; 109:22667-22673.
86. Pokala N, Handel T. Energy functions for protein design: adjustment with protein-protein complex affinities, models for the unfolded state, and negative design of solubility and specificity. J Mol Biol 2005;347:2003-2027.
87. Lopes A, Alexandrov A, Bathelt C, Archontis G, Simonson T. Computational sidechain placement and protein mutagenesis with implicit solvent models. Proteins 2007;67:853-867.
88. Beglov D, Roux B. Finite representation of an infinite bulk system-solvent boundary potential for computer-simulations. J Chem Phys 1994;100:9050-9053.
89. Simonson T, Archontis G, Karplus M. Continuum treatment of long-range interactions in free energy calculations. Application to protein-ligand binding. Phys Chem B 1997;101:8349-8362.
90. Lounnas V, Ludemann SK, Wade RC. Towards molecular dynamics simulation of large proteins with a hydration shell at constant pressure. Biophys Chem 1999;78:157-182.
91. Lee MS, Salsbury FR, Olson MA. An efficient hybrid explicit/implicit solvent method for biomolecular simulations. J Comput Chem 2004;25:1967-1978.
92. Dunitz JD. The entropic cost of bound water in crystals and biomolecules. Science 1994;264:670.